GlassScriptPhysician profile
Leslie A Britton
NPI 1992350730
$3,330.34
in general payments reported to CMS, 2019-2025
38 companies · $710 in 2025
The $710 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $312 · 2023: $1,287 · 2024: $917 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $453.92 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $319.22 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $259.80 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $191.50 | 2023-2024 | Repatha, Prolia, Evenity |
| Boston Scientific Corporation | $191.32 | 2021-2025 | Eluvia, Ekosonic |
| Idorsia Pharmaceuticals US INC | $182.39 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.56 | 2023-2025 | Xifaxan |
| Abbvie INC. | $161.61 | 2023-2025 | |
| Lilly USA, LLC | $140.94 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $136.49 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.48 | 2023-2025 | Jardiance, Ofev |
| Dexcom, INC. | $114.27 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $100.54 | 2022-2024 | |
| Esperion Therapeutics, INC. | $94.87 | 2021-2024 | Nexletol |
| Daiichi Sankyo INC. | $90.75 | 2024 | Injectafer |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Britton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.